Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus. / Schwartz, Franziska A.; Lerche, Christian J.; Christophersen, Lars; Jensen, Peter Østrup; Laulund, Anne Sofie; Woetmann, Anders; Høiby, Niels; Moser, Claus.

In: Acta Pathologica Microbiologica et Immunologica Scandinavica, Vol. 129, No. 9, 2021, p. 566-573.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Schwartz, FA, Lerche, CJ, Christophersen, L, Jensen, PØ, Laulund, AS, Woetmann, A, Høiby, N & Moser, C 2021, 'Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus', Acta Pathologica Microbiologica et Immunologica Scandinavica, vol. 129, no. 9, pp. 566-573. https://doi.org/10.1111/apm.13164

APA

Schwartz, F. A., Lerche, C. J., Christophersen, L., Jensen, P. Ø., Laulund, A. S., Woetmann, A., Høiby, N., & Moser, C. (2021). Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus. Acta Pathologica Microbiologica et Immunologica Scandinavica, 129(9), 566-573. https://doi.org/10.1111/apm.13164

Vancouver

Schwartz FA, Lerche CJ, Christophersen L, Jensen PØ, Laulund AS, Woetmann A et al. Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus. Acta Pathologica Microbiologica et Immunologica Scandinavica. 2021;129(9):566-573. https://doi.org/10.1111/apm.13164

Author

Schwartz, Franziska A. ; Lerche, Christian J. ; Christophersen, Lars ; Jensen, Peter Østrup ; Laulund, Anne Sofie ; Woetmann, Anders ; Høiby, Niels ; Moser, Claus. / Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus. In: Acta Pathologica Microbiologica et Immunologica Scandinavica. 2021 ; Vol. 129, No. 9. pp. 566-573.

Bibtex

@article{b4a1917147d4460c9d0303560b0029e6,
title = "Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus",
abstract = "Staphylococcus aureus (SA) causes superficial and severe endovascular infections. The present in vitro study investigates the anti-SA mechanisms of hyperbaric oxygen therapy (HBOT) on direct bacterial killing, antibiotic potentiation, and polymorphonuclear leukocyte (PMN) enhancement. SA was exposed to isolated human PMNs, tobramycin, ciprofloxacin, or benzylpenicillin. HBOT was used as one 90-min session. Bacterial survival was evaluated after 4 h by quantitative bacteriology. PMN functionality as reactive oxygen species (ROS) production was measured by means of dihydrorhodamine 123 analysis. We showed that HBOT exhibits significant direct anti-SA effects. HBOT increased the anti-SA effects of PMNs by 18% after PMA stimulation (p = 0.0004) and by 15% in response to SA (p = 0.36). HBOT showed an additive effect as growth reductions of 26% to sub-MICs of tobramycin (p = 0.0057), 44% to sub-MICs of ciprofloxacin (p = 0.0001), and 26% to sub-MICs of penicillin (p = 0.038). The present in vitro study provides evidence that HBOT has differential mechanisms mediating its anti-SA effects. Our observation supports the clinical possibility for adjunctive HBOT to augment the host immune response and optimize the efficacy of antibiotic treatments.",
keywords = "host response, hyperbaric oxygen therapy, Infection, neutrophils, oxidative stress",
author = "Schwartz, {Franziska A.} and Lerche, {Christian J.} and Lars Christophersen and Jensen, {Peter {\O}strup} and Laulund, {Anne Sofie} and Anders Woetmann and Niels H{\o}iby and Claus Moser",
note = "Publisher Copyright: {\textcopyright} 2021 Scandinavian Societies for Medical Microbiology and Pathology.",
year = "2021",
doi = "10.1111/apm.13164",
language = "English",
volume = "129",
pages = "566--573",
journal = "A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica",
issn = "0903-4641",
publisher = "Wiley Online",
number = "9",

}

RIS

TY - JOUR

T1 - Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against Staphylococcus aureus

AU - Schwartz, Franziska A.

AU - Lerche, Christian J.

AU - Christophersen, Lars

AU - Jensen, Peter Østrup

AU - Laulund, Anne Sofie

AU - Woetmann, Anders

AU - Høiby, Niels

AU - Moser, Claus

N1 - Publisher Copyright: © 2021 Scandinavian Societies for Medical Microbiology and Pathology.

PY - 2021

Y1 - 2021

N2 - Staphylococcus aureus (SA) causes superficial and severe endovascular infections. The present in vitro study investigates the anti-SA mechanisms of hyperbaric oxygen therapy (HBOT) on direct bacterial killing, antibiotic potentiation, and polymorphonuclear leukocyte (PMN) enhancement. SA was exposed to isolated human PMNs, tobramycin, ciprofloxacin, or benzylpenicillin. HBOT was used as one 90-min session. Bacterial survival was evaluated after 4 h by quantitative bacteriology. PMN functionality as reactive oxygen species (ROS) production was measured by means of dihydrorhodamine 123 analysis. We showed that HBOT exhibits significant direct anti-SA effects. HBOT increased the anti-SA effects of PMNs by 18% after PMA stimulation (p = 0.0004) and by 15% in response to SA (p = 0.36). HBOT showed an additive effect as growth reductions of 26% to sub-MICs of tobramycin (p = 0.0057), 44% to sub-MICs of ciprofloxacin (p = 0.0001), and 26% to sub-MICs of penicillin (p = 0.038). The present in vitro study provides evidence that HBOT has differential mechanisms mediating its anti-SA effects. Our observation supports the clinical possibility for adjunctive HBOT to augment the host immune response and optimize the efficacy of antibiotic treatments.

AB - Staphylococcus aureus (SA) causes superficial and severe endovascular infections. The present in vitro study investigates the anti-SA mechanisms of hyperbaric oxygen therapy (HBOT) on direct bacterial killing, antibiotic potentiation, and polymorphonuclear leukocyte (PMN) enhancement. SA was exposed to isolated human PMNs, tobramycin, ciprofloxacin, or benzylpenicillin. HBOT was used as one 90-min session. Bacterial survival was evaluated after 4 h by quantitative bacteriology. PMN functionality as reactive oxygen species (ROS) production was measured by means of dihydrorhodamine 123 analysis. We showed that HBOT exhibits significant direct anti-SA effects. HBOT increased the anti-SA effects of PMNs by 18% after PMA stimulation (p = 0.0004) and by 15% in response to SA (p = 0.36). HBOT showed an additive effect as growth reductions of 26% to sub-MICs of tobramycin (p = 0.0057), 44% to sub-MICs of ciprofloxacin (p = 0.0001), and 26% to sub-MICs of penicillin (p = 0.038). The present in vitro study provides evidence that HBOT has differential mechanisms mediating its anti-SA effects. Our observation supports the clinical possibility for adjunctive HBOT to augment the host immune response and optimize the efficacy of antibiotic treatments.

KW - host response

KW - hyperbaric oxygen therapy

KW - Infection

KW - neutrophils

KW - oxidative stress

U2 - 10.1111/apm.13164

DO - 10.1111/apm.13164

M3 - Journal article

C2 - 34120378

AN - SCOPUS:85109186916

VL - 129

SP - 566

EP - 573

JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

SN - 0903-4641

IS - 9

ER -

ID: 274620681